Healthy men test new version of cancer drug and how food affects it
NCT ID NCT05380947
First seen Nov 05, 2025
Summary
This completed Phase 1 trial enrolled 13 healthy men to compare two oral formulations of the drug BI 1810631. Researchers also tested how taking the drug with food or after multiple doses of the acid-reducer rabeprazole changes its absorption. The goal is to guide future dosing and formulation choices for this potential cancer treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Humanpharmakologisches Zentrum Biberach
Biberach, 88397, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 1810631 (Zongertinib)
What this could lead to
If successful, this study could help determine the best formulation and dosing instructions for BI 1810631 in future trials.
What could go wrong
This is a small, early-stage study in healthy volunteers, not patients. Results may not predict effects in people with the target disease.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.